Purpose The randomized HD2000 trial compared six cycles of ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine), four escalated plus two standard cycles of BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone), and six cycles of COPPEBV- CAD (cyclophosphamide, lomustine, vindesine, melphalan, prednisone, epidoxorubicin, vincristine, procarbazine, vinblastine, and bleomycin; CEC) in patients with advanced-stage Hodgkin lymphoma. After a median follow-up of 42 months, patients who received BEACOPP were reported to have experienced better progression-free survival (PFS) but not better overall survival (OS) results than those receiving ABVD. Wehere report a post hoc analysis of this trial after a median follow-up of 10 years. Patients and Methods Three hundred seven patients were enrolled, 295 of whom were evaluable. At the time of our analysis, the median follow-up for the entire group was 120 months (range, 4 to 169 months). Results The 10-year PFS results for the ABVD, BEACOPP, and CEC arms were 69%, 75%, and 76%, respectively; corresponding OS results were 85%, 84%, and 86%. Overall, 13 second malignancies were reported: one in the ABVD arm and six each in the BEACOPP and CEC arms. The cumulative risk of developing secondmalignancies at 10 years was 0.9%, 6.6%, and 6% with ABVD, BEACOPP, and CEC, respectively; the risk with either BEACOPP or CEC was significantly higher than that reported with ABVD (P = .027 and .02, respectively). Conclusion With these mature results, we confirm that patients with advanced Hodgkin lymphoma have similar OS results when treated with ABVD, BEACOPP, or CEC. However, with longer follow-up, we were not able to confirm the superiority of BEACOPP over ABVD in terms of PFS, mainly because of higher mortality rates resulting from second malignancies observed after treatment with BEACOPP and CEC.

Long-term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP-EBV-CAD in untreated patients with advanced hodgkin lymphoma: A study by fondazione Italiana Linfomi / Merli, Francesco; Luminari, Stefano; Gobbi, Paolo G.; Cascavilla, Nicola; Mammi, Caterina; Ilariucci, Fiorella; Stelitano, Caterina; Musso, Maurizio; Baldini, Luca; Galimberti, Sara; Angrilli, Francesco; Polimeno, Giuseppe; Scalzulli, Potito Rosario; Ferrari, Angela; Marcheselli, Luigi; Federico, Massimo. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - 34:(2016), pp. 1175-1181. [10.1200/JCO.2015.62.4817]

Long-term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP-EBV-CAD in untreated patients with advanced hodgkin lymphoma: A study by fondazione Italiana Linfomi

LUMINARI, Stefano;MAMMI, Caterina;MARCHESELLI, Luigi;FEDERICO, Massimo
2016

Abstract

Purpose The randomized HD2000 trial compared six cycles of ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine), four escalated plus two standard cycles of BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone), and six cycles of COPPEBV- CAD (cyclophosphamide, lomustine, vindesine, melphalan, prednisone, epidoxorubicin, vincristine, procarbazine, vinblastine, and bleomycin; CEC) in patients with advanced-stage Hodgkin lymphoma. After a median follow-up of 42 months, patients who received BEACOPP were reported to have experienced better progression-free survival (PFS) but not better overall survival (OS) results than those receiving ABVD. Wehere report a post hoc analysis of this trial after a median follow-up of 10 years. Patients and Methods Three hundred seven patients were enrolled, 295 of whom were evaluable. At the time of our analysis, the median follow-up for the entire group was 120 months (range, 4 to 169 months). Results The 10-year PFS results for the ABVD, BEACOPP, and CEC arms were 69%, 75%, and 76%, respectively; corresponding OS results were 85%, 84%, and 86%. Overall, 13 second malignancies were reported: one in the ABVD arm and six each in the BEACOPP and CEC arms. The cumulative risk of developing secondmalignancies at 10 years was 0.9%, 6.6%, and 6% with ABVD, BEACOPP, and CEC, respectively; the risk with either BEACOPP or CEC was significantly higher than that reported with ABVD (P = .027 and .02, respectively). Conclusion With these mature results, we confirm that patients with advanced Hodgkin lymphoma have similar OS results when treated with ABVD, BEACOPP, or CEC. However, with longer follow-up, we were not able to confirm the superiority of BEACOPP over ABVD in terms of PFS, mainly because of higher mortality rates resulting from second malignancies observed after treatment with BEACOPP and CEC.
2016
28-dic-2015
34
1175
1181
Long-term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP-EBV-CAD in untreated patients with advanced hodgkin lymphoma: A study by fondazione Italiana Linfomi / Merli, Francesco; Luminari, Stefano; Gobbi, Paolo G.; Cascavilla, Nicola; Mammi, Caterina; Ilariucci, Fiorella; Stelitano, Caterina; Musso, Maurizio; Baldini, Luca; Galimberti, Sara; Angrilli, Francesco; Polimeno, Giuseppe; Scalzulli, Potito Rosario; Ferrari, Angela; Marcheselli, Luigi; Federico, Massimo. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - 34:(2016), pp. 1175-1181. [10.1200/JCO.2015.62.4817]
Merli, Francesco; Luminari, Stefano; Gobbi, Paolo G.; Cascavilla, Nicola; Mammi, Caterina; Ilariucci, Fiorella; Stelitano, Caterina; Musso, Maurizio; Baldini, Luca; Galimberti, Sara; Angrilli, Francesco; Polimeno, Giuseppe; Scalzulli, Potito Rosario; Ferrari, Angela; Marcheselli, Luigi; Federico, Massimo
File in questo prodotto:
File Dimensione Formato  
427 (ex 761).pdf

Accesso riservato

Tipologia: Versione pubblicata dall'editore
Dimensione 843.45 kB
Formato Adobe PDF
843.45 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1105308
Citazioni
  • ???jsp.display-item.citation.pmc??? 26
  • Scopus 85
  • ???jsp.display-item.citation.isi??? 77
social impact